Concizumab
Tissue Factor Pathway Inhibitor Antagonist — BLOOD AND BLOOD FORMING ORGANS
Also known as: alhemo, NN7415, NNC 0172-0000-2021, NNC172-2021
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Concizumab is a drug in the Tissue Factor Pathway Inhibitor Antagonist class catalogued in DrugCentral. It was first approved by the PMDA in 2023. Its mechanism of action is classified as Tissue Factor Pathway Inhibitor Antagonists. DrugCentral lists 1 molecular target, including TFPI. Recorded indications include Prophylactic treatment of hemophilia A and B.
- Drug class: Tissue Factor Pathway Inhibitor Antagonist.
- Mechanism of action: Tissue Factor Pathway Inhibitor Antagonists.
- Molecular targets: TFPI (1 listed in DrugCentral).
- Indications: Prophylactic treatment of hemophilia A and B.
- ATC code: B02BX10 (Other systemic hemostatics).
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Prophylactic treatment of hemophilia A and B
Mechanism & targets
| Mechanism of action (MoA) | Tissue Factor Pathway Inhibitor Antagonists |
|---|---|
| Established pharmacologic class | Tissue Factor Pathway Inhibitor Antagonist |
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Tissue factor pathway inhibitor | TFPI | other | Kd 10.60 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2023-09-25 | PMDA | — | Novo Nordisk Pharma |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
B02BX10 | BLOOD AND BLOOD FORMING ORGANS › ANTIHEMORRHAGICS › VITAMIN K AND OTHER HEMOSTATICS › Other systemic hemostatics |
Chemical structure
| Molecular formula | — |
|---|---|
| Molecular weight | — |
| CAS number | — |
| InChIKey | — |
| PubChem CID | — |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Concizumab used for?
DrugCentral lists the following indications for Concizumab: Prophylactic treatment of hemophilia A and B.
How does Concizumab work?
Concizumab is classified as Tissue Factor Pathway Inhibitor Antagonists; its molecular targets in DrugCentral include TFPI.
When was Concizumab first approved?
Concizumab was first approved by the PMDA in 2023.
What drug class does Concizumab belong to?
Concizumab is in the Tissue Factor Pathway Inhibitor Antagonist class.
Browse: all drugs starting with C · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5760 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL4297730 — compound record and bioactivity
- DrugBank DB12820 — drug record
- FDA UNII 68603V9EAF — substance identity
- UniProt P10646 (TFPI) — target protein
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.